Cargando…

Oral Contraceptive Use and Breast Cancer Risk: Retrospective and Prospective Analyses From a BRCA1 and BRCA2 Mutation Carrier Cohort Study

BACKGROUND: For BRCA1 and BRCA2 mutation carriers, the association between oral contraceptive preparation (OCP) use and breast cancer (BC) risk is still unclear. METHODS: Breast camcer risk associations were estimated from OCP data on 6030 BRCA1 and 3809 BRCA2 mutation carriers using age-dependent C...

Descripción completa

Detalles Bibliográficos
Autores principales: Schrijver, Lieske H, Olsson, Håkan, Phillips, Kelly-Anne, Terry, Mary Beth, Goldgar, David E, Kast, Karin, Engel, Christoph, Mooij, Thea M, Adlard, Julian, Barrowdale, Daniel, Davidson, Rosemarie, Eeles, Ros, Ellis, Steve, Evans, D Gareth, Frost, Debra, Izatt, Louise, Porteous, Mary E, Side, Lucy E, Walker, Lisa, Berthet, Pascaline, Bonadona, Valérie, Leroux, Dominique, Mouret-Fourme, Emmanuelle, Venat-Bouvet, Laurence, Buys, Saundra S, Southey, Melissa C, John, Esther M, Chung, Wendy K, Daly, Mary B, Bane, Anita, van Asperen, Christi J, Gómez Garcia, Encarna B, Mourits, Marian J E, van Os, Theo A M, Roos-Blom, Marie-José, Friedlander, Michael L, McLachlan, Sue-Anne, Singer, Christian F, Tan, Yen Y, Foretova, Lenka, Navratilova, Marie, Gerdes, Anne-Marie, Caldes, Trinidad, Simard, Jacques, Olah, Edith, Jakubowska, Anna, Arver, Brita, Osorio, Ana, Noguès, Catherine, Andrieu, Nadine, Easton, Douglas F, van Leeuwen, Flora E, Hopper, John L, Milne, Roger L, Antoniou, Antonis C, Rookus, Matti A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6649757/
https://www.ncbi.nlm.nih.gov/pubmed/31360853
http://dx.doi.org/10.1093/jncics/pky023
_version_ 1783438045920362496
author Schrijver, Lieske H
Olsson, Håkan
Phillips, Kelly-Anne
Terry, Mary Beth
Goldgar, David E
Kast, Karin
Engel, Christoph
Mooij, Thea M
Adlard, Julian
Barrowdale, Daniel
Davidson, Rosemarie
Eeles, Ros
Ellis, Steve
Evans, D Gareth
Frost, Debra
Izatt, Louise
Porteous, Mary E
Side, Lucy E
Walker, Lisa
Berthet, Pascaline
Bonadona, Valérie
Leroux, Dominique
Mouret-Fourme, Emmanuelle
Venat-Bouvet, Laurence
Buys, Saundra S
Southey, Melissa C
John, Esther M
Chung, Wendy K
Daly, Mary B
Bane, Anita
van Asperen, Christi J
Gómez Garcia, Encarna B
Mourits, Marian J E
van Os, Theo A M
Roos-Blom, Marie-José
Friedlander, Michael L
McLachlan, Sue-Anne
Singer, Christian F
Tan, Yen Y
Foretova, Lenka
Navratilova, Marie
Gerdes, Anne-Marie
Caldes, Trinidad
Simard, Jacques
Olah, Edith
Jakubowska, Anna
Arver, Brita
Osorio, Ana
Noguès, Catherine
Andrieu, Nadine
Easton, Douglas F
van Leeuwen, Flora E
Hopper, John L
Milne, Roger L
Antoniou, Antonis C
Rookus, Matti A
author_facet Schrijver, Lieske H
Olsson, Håkan
Phillips, Kelly-Anne
Terry, Mary Beth
Goldgar, David E
Kast, Karin
Engel, Christoph
Mooij, Thea M
Adlard, Julian
Barrowdale, Daniel
Davidson, Rosemarie
Eeles, Ros
Ellis, Steve
Evans, D Gareth
Frost, Debra
Izatt, Louise
Porteous, Mary E
Side, Lucy E
Walker, Lisa
Berthet, Pascaline
Bonadona, Valérie
Leroux, Dominique
Mouret-Fourme, Emmanuelle
Venat-Bouvet, Laurence
Buys, Saundra S
Southey, Melissa C
John, Esther M
Chung, Wendy K
Daly, Mary B
Bane, Anita
van Asperen, Christi J
Gómez Garcia, Encarna B
Mourits, Marian J E
van Os, Theo A M
Roos-Blom, Marie-José
Friedlander, Michael L
McLachlan, Sue-Anne
Singer, Christian F
Tan, Yen Y
Foretova, Lenka
Navratilova, Marie
Gerdes, Anne-Marie
Caldes, Trinidad
Simard, Jacques
Olah, Edith
Jakubowska, Anna
Arver, Brita
Osorio, Ana
Noguès, Catherine
Andrieu, Nadine
Easton, Douglas F
van Leeuwen, Flora E
Hopper, John L
Milne, Roger L
Antoniou, Antonis C
Rookus, Matti A
author_sort Schrijver, Lieske H
collection PubMed
description BACKGROUND: For BRCA1 and BRCA2 mutation carriers, the association between oral contraceptive preparation (OCP) use and breast cancer (BC) risk is still unclear. METHODS: Breast camcer risk associations were estimated from OCP data on 6030 BRCA1 and 3809 BRCA2 mutation carriers using age-dependent Cox regression, stratified by study and birth cohort. Prospective, left-truncated retrospective and full-cohort retrospective analyses were performed. RESULTS: For BRCA1 mutation carriers, OCP use was not associated with BC risk in prospective analyses (hazard ratio [HR] = 1.08, 95% confidence interval [CI] = 0.75 to 1.56), but in the left-truncated and full-cohort retrospective analyses, risks were increased by 26% (95% CI = 6% to 51%) and 39% (95% CI = 23% to 58%), respectively. For BRCA2 mutation carriers, OCP use was associated with BC risk in prospective analyses (HR = 1.75, 95% CI = 1.03 to 2.97), but retrospective analyses were inconsistent (left-truncated: HR = 1.06, 95% CI = 0.85 to 1.33; full cohort: HR = 1.52, 95% CI = 1.28 to 1.81). There was evidence of increasing risk with duration of use, especially before the first full-term pregnancy (BRCA1: both retrospective analyses, P < .001 and P = .001, respectively; BRCA2: full retrospective analysis, P = .002). CONCLUSIONS: Prospective analyses did not show that past use of OCP is associated with an increased BC risk for BRCA1 mutation carriers in young middle-aged women (40–50 years). For BRCA2 mutation carriers, a causal association is also not likely at those ages. Findings between retrospective and prospective analyses were inconsistent and could be due to survival bias or a true association for younger women who were underrepresented in the prospective cohort. Given the uncertain safety of long-term OCP use for BRCA1/2 mutation carriers, indications other than contraception should be avoided and nonhormonal contraceptive methods should be discussed.
format Online
Article
Text
id pubmed-6649757
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-66497572019-07-29 Oral Contraceptive Use and Breast Cancer Risk: Retrospective and Prospective Analyses From a BRCA1 and BRCA2 Mutation Carrier Cohort Study Schrijver, Lieske H Olsson, Håkan Phillips, Kelly-Anne Terry, Mary Beth Goldgar, David E Kast, Karin Engel, Christoph Mooij, Thea M Adlard, Julian Barrowdale, Daniel Davidson, Rosemarie Eeles, Ros Ellis, Steve Evans, D Gareth Frost, Debra Izatt, Louise Porteous, Mary E Side, Lucy E Walker, Lisa Berthet, Pascaline Bonadona, Valérie Leroux, Dominique Mouret-Fourme, Emmanuelle Venat-Bouvet, Laurence Buys, Saundra S Southey, Melissa C John, Esther M Chung, Wendy K Daly, Mary B Bane, Anita van Asperen, Christi J Gómez Garcia, Encarna B Mourits, Marian J E van Os, Theo A M Roos-Blom, Marie-José Friedlander, Michael L McLachlan, Sue-Anne Singer, Christian F Tan, Yen Y Foretova, Lenka Navratilova, Marie Gerdes, Anne-Marie Caldes, Trinidad Simard, Jacques Olah, Edith Jakubowska, Anna Arver, Brita Osorio, Ana Noguès, Catherine Andrieu, Nadine Easton, Douglas F van Leeuwen, Flora E Hopper, John L Milne, Roger L Antoniou, Antonis C Rookus, Matti A JNCI Cancer Spectr Article BACKGROUND: For BRCA1 and BRCA2 mutation carriers, the association between oral contraceptive preparation (OCP) use and breast cancer (BC) risk is still unclear. METHODS: Breast camcer risk associations were estimated from OCP data on 6030 BRCA1 and 3809 BRCA2 mutation carriers using age-dependent Cox regression, stratified by study and birth cohort. Prospective, left-truncated retrospective and full-cohort retrospective analyses were performed. RESULTS: For BRCA1 mutation carriers, OCP use was not associated with BC risk in prospective analyses (hazard ratio [HR] = 1.08, 95% confidence interval [CI] = 0.75 to 1.56), but in the left-truncated and full-cohort retrospective analyses, risks were increased by 26% (95% CI = 6% to 51%) and 39% (95% CI = 23% to 58%), respectively. For BRCA2 mutation carriers, OCP use was associated with BC risk in prospective analyses (HR = 1.75, 95% CI = 1.03 to 2.97), but retrospective analyses were inconsistent (left-truncated: HR = 1.06, 95% CI = 0.85 to 1.33; full cohort: HR = 1.52, 95% CI = 1.28 to 1.81). There was evidence of increasing risk with duration of use, especially before the first full-term pregnancy (BRCA1: both retrospective analyses, P < .001 and P = .001, respectively; BRCA2: full retrospective analysis, P = .002). CONCLUSIONS: Prospective analyses did not show that past use of OCP is associated with an increased BC risk for BRCA1 mutation carriers in young middle-aged women (40–50 years). For BRCA2 mutation carriers, a causal association is also not likely at those ages. Findings between retrospective and prospective analyses were inconsistent and could be due to survival bias or a true association for younger women who were underrepresented in the prospective cohort. Given the uncertain safety of long-term OCP use for BRCA1/2 mutation carriers, indications other than contraception should be avoided and nonhormonal contraceptive methods should be discussed. Oxford University Press 2018-06-28 /pmc/articles/PMC6649757/ /pubmed/31360853 http://dx.doi.org/10.1093/jncics/pky023 Text en copy; The Author(s) 2018. Published by Oxford University Press. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Article
Schrijver, Lieske H
Olsson, Håkan
Phillips, Kelly-Anne
Terry, Mary Beth
Goldgar, David E
Kast, Karin
Engel, Christoph
Mooij, Thea M
Adlard, Julian
Barrowdale, Daniel
Davidson, Rosemarie
Eeles, Ros
Ellis, Steve
Evans, D Gareth
Frost, Debra
Izatt, Louise
Porteous, Mary E
Side, Lucy E
Walker, Lisa
Berthet, Pascaline
Bonadona, Valérie
Leroux, Dominique
Mouret-Fourme, Emmanuelle
Venat-Bouvet, Laurence
Buys, Saundra S
Southey, Melissa C
John, Esther M
Chung, Wendy K
Daly, Mary B
Bane, Anita
van Asperen, Christi J
Gómez Garcia, Encarna B
Mourits, Marian J E
van Os, Theo A M
Roos-Blom, Marie-José
Friedlander, Michael L
McLachlan, Sue-Anne
Singer, Christian F
Tan, Yen Y
Foretova, Lenka
Navratilova, Marie
Gerdes, Anne-Marie
Caldes, Trinidad
Simard, Jacques
Olah, Edith
Jakubowska, Anna
Arver, Brita
Osorio, Ana
Noguès, Catherine
Andrieu, Nadine
Easton, Douglas F
van Leeuwen, Flora E
Hopper, John L
Milne, Roger L
Antoniou, Antonis C
Rookus, Matti A
Oral Contraceptive Use and Breast Cancer Risk: Retrospective and Prospective Analyses From a BRCA1 and BRCA2 Mutation Carrier Cohort Study
title Oral Contraceptive Use and Breast Cancer Risk: Retrospective and Prospective Analyses From a BRCA1 and BRCA2 Mutation Carrier Cohort Study
title_full Oral Contraceptive Use and Breast Cancer Risk: Retrospective and Prospective Analyses From a BRCA1 and BRCA2 Mutation Carrier Cohort Study
title_fullStr Oral Contraceptive Use and Breast Cancer Risk: Retrospective and Prospective Analyses From a BRCA1 and BRCA2 Mutation Carrier Cohort Study
title_full_unstemmed Oral Contraceptive Use and Breast Cancer Risk: Retrospective and Prospective Analyses From a BRCA1 and BRCA2 Mutation Carrier Cohort Study
title_short Oral Contraceptive Use and Breast Cancer Risk: Retrospective and Prospective Analyses From a BRCA1 and BRCA2 Mutation Carrier Cohort Study
title_sort oral contraceptive use and breast cancer risk: retrospective and prospective analyses from a brca1 and brca2 mutation carrier cohort study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6649757/
https://www.ncbi.nlm.nih.gov/pubmed/31360853
http://dx.doi.org/10.1093/jncics/pky023
work_keys_str_mv AT schrijverlieskeh oralcontraceptiveuseandbreastcancerriskretrospectiveandprospectiveanalysesfromabrca1andbrca2mutationcarriercohortstudy
AT olssonhakan oralcontraceptiveuseandbreastcancerriskretrospectiveandprospectiveanalysesfromabrca1andbrca2mutationcarriercohortstudy
AT phillipskellyanne oralcontraceptiveuseandbreastcancerriskretrospectiveandprospectiveanalysesfromabrca1andbrca2mutationcarriercohortstudy
AT terrymarybeth oralcontraceptiveuseandbreastcancerriskretrospectiveandprospectiveanalysesfromabrca1andbrca2mutationcarriercohortstudy
AT goldgardavide oralcontraceptiveuseandbreastcancerriskretrospectiveandprospectiveanalysesfromabrca1andbrca2mutationcarriercohortstudy
AT kastkarin oralcontraceptiveuseandbreastcancerriskretrospectiveandprospectiveanalysesfromabrca1andbrca2mutationcarriercohortstudy
AT engelchristoph oralcontraceptiveuseandbreastcancerriskretrospectiveandprospectiveanalysesfromabrca1andbrca2mutationcarriercohortstudy
AT mooijtheam oralcontraceptiveuseandbreastcancerriskretrospectiveandprospectiveanalysesfromabrca1andbrca2mutationcarriercohortstudy
AT adlardjulian oralcontraceptiveuseandbreastcancerriskretrospectiveandprospectiveanalysesfromabrca1andbrca2mutationcarriercohortstudy
AT barrowdaledaniel oralcontraceptiveuseandbreastcancerriskretrospectiveandprospectiveanalysesfromabrca1andbrca2mutationcarriercohortstudy
AT davidsonrosemarie oralcontraceptiveuseandbreastcancerriskretrospectiveandprospectiveanalysesfromabrca1andbrca2mutationcarriercohortstudy
AT eelesros oralcontraceptiveuseandbreastcancerriskretrospectiveandprospectiveanalysesfromabrca1andbrca2mutationcarriercohortstudy
AT ellissteve oralcontraceptiveuseandbreastcancerriskretrospectiveandprospectiveanalysesfromabrca1andbrca2mutationcarriercohortstudy
AT evansdgareth oralcontraceptiveuseandbreastcancerriskretrospectiveandprospectiveanalysesfromabrca1andbrca2mutationcarriercohortstudy
AT frostdebra oralcontraceptiveuseandbreastcancerriskretrospectiveandprospectiveanalysesfromabrca1andbrca2mutationcarriercohortstudy
AT izattlouise oralcontraceptiveuseandbreastcancerriskretrospectiveandprospectiveanalysesfromabrca1andbrca2mutationcarriercohortstudy
AT porteousmarye oralcontraceptiveuseandbreastcancerriskretrospectiveandprospectiveanalysesfromabrca1andbrca2mutationcarriercohortstudy
AT sidelucye oralcontraceptiveuseandbreastcancerriskretrospectiveandprospectiveanalysesfromabrca1andbrca2mutationcarriercohortstudy
AT walkerlisa oralcontraceptiveuseandbreastcancerriskretrospectiveandprospectiveanalysesfromabrca1andbrca2mutationcarriercohortstudy
AT berthetpascaline oralcontraceptiveuseandbreastcancerriskretrospectiveandprospectiveanalysesfromabrca1andbrca2mutationcarriercohortstudy
AT bonadonavalerie oralcontraceptiveuseandbreastcancerriskretrospectiveandprospectiveanalysesfromabrca1andbrca2mutationcarriercohortstudy
AT lerouxdominique oralcontraceptiveuseandbreastcancerriskretrospectiveandprospectiveanalysesfromabrca1andbrca2mutationcarriercohortstudy
AT mouretfourmeemmanuelle oralcontraceptiveuseandbreastcancerriskretrospectiveandprospectiveanalysesfromabrca1andbrca2mutationcarriercohortstudy
AT venatbouvetlaurence oralcontraceptiveuseandbreastcancerriskretrospectiveandprospectiveanalysesfromabrca1andbrca2mutationcarriercohortstudy
AT buyssaundras oralcontraceptiveuseandbreastcancerriskretrospectiveandprospectiveanalysesfromabrca1andbrca2mutationcarriercohortstudy
AT southeymelissac oralcontraceptiveuseandbreastcancerriskretrospectiveandprospectiveanalysesfromabrca1andbrca2mutationcarriercohortstudy
AT johnestherm oralcontraceptiveuseandbreastcancerriskretrospectiveandprospectiveanalysesfromabrca1andbrca2mutationcarriercohortstudy
AT chungwendyk oralcontraceptiveuseandbreastcancerriskretrospectiveandprospectiveanalysesfromabrca1andbrca2mutationcarriercohortstudy
AT dalymaryb oralcontraceptiveuseandbreastcancerriskretrospectiveandprospectiveanalysesfromabrca1andbrca2mutationcarriercohortstudy
AT baneanita oralcontraceptiveuseandbreastcancerriskretrospectiveandprospectiveanalysesfromabrca1andbrca2mutationcarriercohortstudy
AT vanasperenchristij oralcontraceptiveuseandbreastcancerriskretrospectiveandprospectiveanalysesfromabrca1andbrca2mutationcarriercohortstudy
AT gomezgarciaencarnab oralcontraceptiveuseandbreastcancerriskretrospectiveandprospectiveanalysesfromabrca1andbrca2mutationcarriercohortstudy
AT mouritsmarianje oralcontraceptiveuseandbreastcancerriskretrospectiveandprospectiveanalysesfromabrca1andbrca2mutationcarriercohortstudy
AT vanostheoam oralcontraceptiveuseandbreastcancerriskretrospectiveandprospectiveanalysesfromabrca1andbrca2mutationcarriercohortstudy
AT roosblommariejose oralcontraceptiveuseandbreastcancerriskretrospectiveandprospectiveanalysesfromabrca1andbrca2mutationcarriercohortstudy
AT friedlandermichaell oralcontraceptiveuseandbreastcancerriskretrospectiveandprospectiveanalysesfromabrca1andbrca2mutationcarriercohortstudy
AT mclachlansueanne oralcontraceptiveuseandbreastcancerriskretrospectiveandprospectiveanalysesfromabrca1andbrca2mutationcarriercohortstudy
AT singerchristianf oralcontraceptiveuseandbreastcancerriskretrospectiveandprospectiveanalysesfromabrca1andbrca2mutationcarriercohortstudy
AT tanyeny oralcontraceptiveuseandbreastcancerriskretrospectiveandprospectiveanalysesfromabrca1andbrca2mutationcarriercohortstudy
AT foretovalenka oralcontraceptiveuseandbreastcancerriskretrospectiveandprospectiveanalysesfromabrca1andbrca2mutationcarriercohortstudy
AT navratilovamarie oralcontraceptiveuseandbreastcancerriskretrospectiveandprospectiveanalysesfromabrca1andbrca2mutationcarriercohortstudy
AT gerdesannemarie oralcontraceptiveuseandbreastcancerriskretrospectiveandprospectiveanalysesfromabrca1andbrca2mutationcarriercohortstudy
AT caldestrinidad oralcontraceptiveuseandbreastcancerriskretrospectiveandprospectiveanalysesfromabrca1andbrca2mutationcarriercohortstudy
AT simardjacques oralcontraceptiveuseandbreastcancerriskretrospectiveandprospectiveanalysesfromabrca1andbrca2mutationcarriercohortstudy
AT olahedith oralcontraceptiveuseandbreastcancerriskretrospectiveandprospectiveanalysesfromabrca1andbrca2mutationcarriercohortstudy
AT jakubowskaanna oralcontraceptiveuseandbreastcancerriskretrospectiveandprospectiveanalysesfromabrca1andbrca2mutationcarriercohortstudy
AT arverbrita oralcontraceptiveuseandbreastcancerriskretrospectiveandprospectiveanalysesfromabrca1andbrca2mutationcarriercohortstudy
AT osorioana oralcontraceptiveuseandbreastcancerriskretrospectiveandprospectiveanalysesfromabrca1andbrca2mutationcarriercohortstudy
AT noguescatherine oralcontraceptiveuseandbreastcancerriskretrospectiveandprospectiveanalysesfromabrca1andbrca2mutationcarriercohortstudy
AT andrieunadine oralcontraceptiveuseandbreastcancerriskretrospectiveandprospectiveanalysesfromabrca1andbrca2mutationcarriercohortstudy
AT eastondouglasf oralcontraceptiveuseandbreastcancerriskretrospectiveandprospectiveanalysesfromabrca1andbrca2mutationcarriercohortstudy
AT vanleeuwenflorae oralcontraceptiveuseandbreastcancerriskretrospectiveandprospectiveanalysesfromabrca1andbrca2mutationcarriercohortstudy
AT hopperjohnl oralcontraceptiveuseandbreastcancerriskretrospectiveandprospectiveanalysesfromabrca1andbrca2mutationcarriercohortstudy
AT milnerogerl oralcontraceptiveuseandbreastcancerriskretrospectiveandprospectiveanalysesfromabrca1andbrca2mutationcarriercohortstudy
AT antoniouantonisc oralcontraceptiveuseandbreastcancerriskretrospectiveandprospectiveanalysesfromabrca1andbrca2mutationcarriercohortstudy
AT rookusmattia oralcontraceptiveuseandbreastcancerriskretrospectiveandprospectiveanalysesfromabrca1andbrca2mutationcarriercohortstudy
AT oralcontraceptiveuseandbreastcancerriskretrospectiveandprospectiveanalysesfromabrca1andbrca2mutationcarriercohortstudy